AbbVie Terminates the Development and Option Agreement with Harpoon Therapeutics for HPN217
Shots:
- AbbVie provided an update to discontinue the exclusive license option of their Development and Option Agreement with Harpoon’s HPN217 program. It will be effective from Oct 12, 2023
- The development of HPN217 in the P-I study will be continued exclusively by Harpoon which is expected to be completed with preliminary data along with favorable safety profile
- A poster presentation has been scheduled from the dose escalation portion (12mg) of the P-I study in patients with r/r multiple myeloma at IMS 2023 annual meeting
Ref: Globenewswire | Image: AbbVie
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
